SOSAFE
29.5.2024 13:13:30 CEST | Business Wire | Press release
SoSafe, Europe’s largest security awareness and human risk management vendor, has appointed four new Executive Advisors. The advisors, comprised of industry experts and technology investors, will provide advice and strategic counsel to the SoSafe leadership team on its ambitious plans to expand their category and product leadership.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240529386435/en/
New hires Ilona Simpson, Carsten Thoma, Christian Karam, Sean Catlett (Photo: Business Wire)
With Forrester predicting that 90% of data breaches in 2024 will involve the human element, reducing human risk is what organisations need to prioritize for business continuity. SoSafe offers a technology-driven solution based on psychology and human-centric design. While SoSafe is committed to empowering digital self-defence around the world, the company is currently leading the category evolution from security awareness and training to human risk management. The Executive Advisors will support this transformative process from both an industry and organisational perspective to increase the company's speed to scale.
The following Executive Advisors will join:
Sean Catlett: Sean is the Chief Information Security and Trust Officer at Bumble. He also served as the Chief Security Officer at Slack, and as Chief Information Security Officer at Reddit and is an advisor to Balance Theory and Hampton North.
"It is clear that cybercriminals are effective at focusing on the human layer of security. AI-powered tools offer them solutions that scale attack success rates, intensifying cyber threats, and I believe the full potential is yet to be seen. We need comprehensive and effective solutions that counter these rising threats by sustainably empowering a strong security culture and reducing human risk - and SoSafe delivers just that in a new and innovative way", states Sean Catlett.
Christian Karam: Christian is an investor and senior advisor on technology investments, previously serving as the Deputy Group Chief Information Security Officer at UBS and the Head of Research & Innovation at INTERPOL.
“Cybercriminals continue to innovate rapidly, outpacing many organisations’ ability to keep up. Mere compliance training videos are no longer enough to overcome this challenge. We must rethink security awareness by building effective and robust security cultures that embrace continuous learning and treat mistakes as key drivers of resilience. SoSafe is leading this transformation towards holistic, people-centric human risk management, and I look forward to contributing to this journey”, says Christian Karam.
Ilona Simpson: Ilona is a trained psychologist and a long-standing CIO across a range of industries and companies, having worked at Netskope, adidas, EON, Aston Martin, DHL, and Porsche.
"We've made a lot of progress over the last few years in terms of the attention that senior management and boards are giving to the human layer of cybersecurity. For CIOs, the human factor and reducing human risk is top of mind. Now, they need effective and simple solutions to help them reduce human risk in a sustainable way”, states Ilona Simpson.
Carsten Thoma: Carsten is the President of Celonis. He has co-founded and scaled Hybris, sold to SAP and became President of SAP CX and member of the Global Executive Team. He serves as an advisor to La Famiglia/General Catalyst, and has been a long-standing investor and entrepreneur.
"SoSafe has the most promising foundation a young company can have: They are solving one of the most important business problems of our time in a fundamentally different way than their competitors. It's my ambition to help them succeed and, together with SoSafe's leadership team, build a global champion from Europe”, states Carsten Thoma.
“We are very honoured that some of the best minds in business and technology have agreed to serve as critical advisors to SoSafe. At this pivotal time in our development, their expertise will enable us to grow even faster, smarter, and more focused. I know I speak for the rest of the executive team when I say that we will value their experienced counsel as we look to accelerate our growth as a company”, states Dr Niklas Hellemann, Psychologist and CEO at SoSafe.
About SoSafe
SoSafe, founded by a team of behavioural scientists and technology experts, is the largest security awareness and human risk management vendor based in Europe. SoSafe is empowering over 4700 customers worldwide to effectively mitigate cyber risk. With a unique human-centric approach grounded in behavioural science, SoSafe enhances secure behaviour across organizations, making it intuitive and second nature. The platform is designed to strengthen digital self-defence by creating robust security cultures that actively involve employees in mitigating human risks. By leveraging psychology and advanced technology and AI, it enables security professionals to effectively identify, prioritize, manage, and ultimately reduce their human risk. The SoSafe team now consists of more than 450 employees in seven locations: Cologne (headquarters), Amsterdam, Berlin, London, Paris, Lisbon, and Munich.
Website: www.sosafe-awareness.com/
LinkedIn: www.linkedin.com/company/sosafe-cyber-security/mycompany/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240529386435/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
